Studies in various bacterial species and cancer cell lines have demonstrated that the evolution of drug resistance can have collateral drug phenotypes that alter susceptibility (i.e. This highlights the need for not only new drugs, but rational approaches to the design of combination therapies that can shorten the length of treatment and prevent the emergence of drug resistance. tuberculosis are difficult to treat, requiring longer treatment regimens along with more toxic side effects. Even for newly approved drugs bedaquiline (BDQ) and pretomanid (PA824) clinical resistance has already been observed, even in treatment-naive populations 3, 4. tuberculosis against all clinically utilized antibiotics 2. However, patient non-compliance and suboptimal drug penetration frequently result in treatment failure, driving the evolution and spread of drug resistance in M. tuberculosis can be treated with a combination of four drugs for six months, that when taken correctly can achieve cure rates of approximately 85% 1. Infections from Mycobacterium tuberculosis remain a significant global health problem. tuberculosis leads to collateral drug responses that can be exploited to design improved drug regimens. This study highlights that the evolution of drug resistance in M. Furthermore, in proof-of-concept studies, we demonstrate how collateral drug phenotypes can be exploited to select against and prevent the emergence of drug-resistant strains. Here, by using drug susceptibility profiling, genomics and evolutionary studies we provide evidence for the existence of collateral drug sensitivities in an isogenic collection M. tuberculosis but has the potential to identify alternative therapeutic strategies to combat drug-resistant strains that are unresponsive to current treatments. This phenomenon of collateral sensitivity is largely unexplored in M. Typically, antibiotic resistance leads to reduced sensitivity, yet in some cases the evolution of drug resistance can lead to enhanced sensitivity to unrelated drugs. Alongside the development of new drugs, optimised drug combinations are needed to improve treatment success and prevent the further spread of antibiotic resistance. The increasing incidence of drug resistance in Mycobacterium tuberculosis has diminished the efficacy of almost all available antibiotics, complicating efforts to combat the spread of this global health burden.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |